Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968097 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00968097: Clinical Trial Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00968097 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968097, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To perform blood metabolite characterization of 123-I MNI-340 in healthy and AD subjects to determine the metabolic fate and nature of metabolites in assessment of 123-I MNI-340 as a single photon computed tomography (SPECT) brain imaging agent
Interventions
- DRUG 123-I MNI-340
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Why NCT00968097 stopped before completion
NCT00968097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which 123-I MNI-340 is the first listed.
NCT00968097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00968097 about?
NCT00968097 is a clinical study titled "Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition". The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged Alzheimer's (AD) subjects and healthy controls To ...
What is the current status of trial NCT00968097?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00968097?
The interventions under investigation include: 123-I MNI-340 (DRUG).
Who is sponsoring clinical trial NCT00968097?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00968097's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia